We’re proud to announce the launch of Alys Pharma, an immuno-dermatology focused company backed with $100m financing by @medicxi and led by world leading scientific experts dedicated to developing transformative medicines for dermatology patients worldwide https://t.co/q1Rh1HZC3d
The next Antiviral Drug Discovery Open Science Forum on Dec 21 focuses on Dengue, with talks from Neelika Malavige (@GMalavige) of @DNDi and Pei-Yong Shi of @utmbhealth!
Register here to join:
https://t.co/NoRTDBrvDA
@jchodera@cdsouthan@covid_moonshot@BindingDb@GuidetoPHARM This entire approach was thoroughly researched @DNDi , after many discussions with hypothetical downstream stakeholders, e.g. multinationals that would consider leading the registration and holding market authorization on an IP-free NCE.
@cdsouthan@jchodera@covid_moonshot@BindingDb@GuidetoPHARM It's a concern about well-intentioned but poorly executed experiments being run on a candidate molecule rather than scooping or willful harm. The regulatory path would still have to account for any experiments or data produced out of moonshot control.
It's here... #SynthesisSaturday special edition:
REAGENT ACRONYM BATTLE ROYALE
PLAY-IN LIGHTNING ROUND... 70 entries need to be culled to 64, so there are 6 play-in votes. Polls in the thread. Just 6 hours to vote!
Like, RT, let's go!
CACHE challenge #3 is open for applications. Use receptor- or ligand-based approaches to predict molecules targeting the MACRO domain of SARS-CoV-2 Nsp3. We will test your compounds experimentally and release the data publicly. https://t.co/oNmbULlhUo @thesgconline@target2035
@MatToddChem@EnamineLtd@OSantibiotics@thesgconline Be careful with those molecules, pretty sure those are known nuisance compounds / PAINS via indiscreet reactivity with cysteines (diverse cysteine attack at the electrophilic CH2 adjacent to the carbonyl, with the thiotriazole as leaving group).